BIIB consolidation might get to end and a new move up possible.

BIIB shares might the consolidation channel and prepare a move higher.
The reason would be that the market discounts the potential sales CAGR for Alzheimer's drugs, reimbursements being an issue.
If the problem gets solved, BIIB gets a clear path towards higher valuation.